Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2008-04-08
2008-04-08
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C530S403000
Reexamination Certificate
active
11093107
ABSTRACT:
The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly repeats.
REFERENCES:
patent: WO 9738011 (1997-10-01), None
Tamura et al., “Acceleration of Influenza Virus Clearance by Th1 Cells in the Nasal Site of Mice Immunized Intranasally with Adjuvant-Combined Recombinant Nucleoprotein,” The Journal of Immunology, 156, pp. 3892-3900 (1996).
See Enclosed Results 18 of 21, Structure search in HCAPLUS (2007).
Falgui et al., “Rationally designed strings of promiscuous CD4+T cell epitopes provide help toHaemophilus influenzaetype b oligosaccharide:a model for new conjugate vaccines”, Eur. J. Immunol. 2001 31:3816-3824.
Fiers et al., “Soluble recombinant influenza vaccines”, Phil. Trans. R. Soc. Lond. B 2001 356:1961-1963.
Gerhard et al., “Identification of Eight Determinants in the Hemagglutinin Molecule of Influenza Virus A/PR/8/34 (H1N1) Which Are Recognized by Class II-Restricted T Cells from BALB/c Mice”, J. Virology 1991 65(1) :364-372.
Heinen et al., “Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus”, J. General Virology 2002 83:1851-1859.
Neirynck et al., “A universal influenza A vaccine based on the extracellular domain of the M2 protein”, Nature Medicine 1999 5(10) :1157-1163.
Zaliauskiene et al., “Enhancement of MHC Class II- Restricted Responses by Receptor-Mediated Uptake of Peptide Antigens1”, J. Immunol 2002 169:2337-2345.
Kragol et al., “Synthesis of a Disulfide-Linked Octameric Peptide Construct carrying Three Different Antigenic Determinants”, Bioorganic & Medicinal Chemistry Letters 2001 11:1417-1420.
Kragol et al., “Orthogonal solid-phase synthesis of tetramannosylated peptide constructs carrying three independent branched epitopes”, Tetrahedron 2001 57:957-966.
Mozdzanowska et al., “Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2”, Vaccine 2003 21:2616-2626.
Gerhard Walter
Otvos, Jr. Laszlo
Licata & Tyrrell PC
Mosher Mary E.
The Wistar Institute
LandOfFree
Multiple antigenic agents and methods for using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiple antigenic agents and methods for using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple antigenic agents and methods for using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3907662